Psychedelics & Cannabis

From substance use disorders in physicians to new research on the efficacy of MDMA-assisted therapy for PTSD, here are highlights from the week in Psychiatric Times.

Here are some updates from the world of psychiatry throughout the month of December.

Reviewing a year of CMEs in Psychiatric Times®

What is new in research on ADHD?

MAPS has submitted an NDA for MDMA-assisted therapy for patients with posttraumatic stress disorder.

What is new in research on cannabis?

The experts weighed in on a wide variety of psychiatric issues for the November 2023 issue of Psychiatric Times.

From late-life treatment-resistant depression to the mental health benefits of gratitude, here are highlights from the week in Psychiatric Times.

Ketamine for anxiety? Researchers performed a systematic review and meta-analysis of ketamine’s anxiolytic effects.

What is new in research on psychedelics?

Young men appear to be particularly susceptible to the effects of cannabis on schizophrenia.

What is new in research on SUDs?

The experts weighed in on a wide variety of psychiatric issues for the October 2023 issue of Psychiatric Times.

Here are some updates from the world of psychiatry throughout the month of October.

Explore the relationship between cannabis use and psychosis.

Residues of past traumatic events can deeply impact our present experiences and our functioning in ways that we are not aware of consciously. We must process and let go of these experiences in order to heal.

From new research on treatment-resistant major depression to strategies for supporting trauma-affected refugee youth, here are highlights from the week in Psychiatric Times.

Get ready for our upcoming virtual, interactive conference with some highlights from 2022.

Is psilocybin a viable treatment for MDD? Researchers performed a phase 2, double blind trial of single-dose psilocybin in patients with treatment resistant depression.

From connections between cannabis use and schizophrenia to some non-psychiatric medications that may worsen symptoms of major depression, here are highlights from the week in Psychiatric Times.

A look at the association between cannabis use and schizophrenia, as well as the need for comprehensive public health policies and education.

What is new in research on psychedelics?

Do SSRIs impact on the antidepressant efficacy of psilocybin? Researchers performed an open-label trial of single-dose psilocybin in patients with TRD who were taking SSRIs.

From cannabis use disorder and schizophrenia to social media use and youth mental health, here are highlights from the week in Psychiatric Times.